Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Read More
We exist to help people of all ages, from day one and every day after.
Learn more about our FDA-approved medicine for pediatric patients with relapsed or refractory pediatric low-grade glioma (pLGG).